# CAMTA1

## Overview
CAMTA1, or calmodulin binding transcription activator 1, is a gene that encodes a transcription factor involved in the regulation of gene expression in response to calcium signals. The protein product of CAMTA1 is characterized by its ability to bind calmodulin, a calcium-binding messenger protein, which classifies it as a calcium-responsive transcriptional regulator. This protein contains several functional domains, including a CG-1 DNA-binding domain, a TIG domain, ankyrin repeats, and IQ motifs, which facilitate its role in transcriptional regulation and interaction with other proteins. CAMTA1 is highly expressed in the brain, particularly in regions associated with memory and motor coordination, and plays a critical role in neuronal survival and function. Additionally, CAMTA1 is implicated in cardiac differentiation and has been identified as a tumor suppressor in various cancers, where its expression is often downregulated. Mutations and alterations in the CAMTA1 gene are associated with neurological disorders such as congenital cerebellar ataxia and certain cancers, highlighting its importance in both normal physiological processes and disease states (Long2014Ataxia; Henrich2011CAMTA1; MullerBorer2012Calcium).

## Structure
CAMTA1 is a transcription factor characterized by several distinct domains that contribute to its function in gene expression regulation. The protein contains a CG-1 DNA-binding domain, which is crucial for its ability to bind to specific DNA sequences and regulate transcription (Long2014Ataxia). It also includes a TIG domain, which is involved in DNA binding and dimerization, allowing CAMTA1 to form dimers on DNA, a feature confirmed by in vitro pull-down assays (Long2014Ataxia). The presence of calmodulin-binding IQ motifs enables CAMTA1 to interact with calmodulin, a calcium-binding messenger protein, indicating its role as a calcium-sensitive regulator (Long2014Ataxia). Ankyrin repeats are also present, which facilitate oligomerization, further influencing its transcriptional activity (Long2014Ataxia).

CAMTA1 is subject to post-translational modifications and exists in multiple splice variant isoforms, which may affect its activity and interactions (Long2014Ataxia). The protein's structure and domain composition suggest a complex regulatory role in cellular processes, particularly in the nervous system, where it is highly expressed (Long2014Ataxia). The CG-1 domain is particularly important for its function as a tumor suppressor in various cancers (Henrich2011CAMTA1).

## Function
CAMTA1 (calmodulin binding transcription activator 1) is a transcription factor that plays a crucial role in regulating gene expression in response to calcium signals. It is part of the calmodulin-binding transcriptional activators (CAMTAs) family, which are calcium-responsive transcriptional regulators. CAMTA1 contains multiple functional domains, including a CG-1 DNA-binding domain, a transcription factor immunoglobulin-like (TIG) domain, ankyrin repeats, and IQ motifs that bind calmodulin-like proteins in response to changes in cellular calcium concentration (Jacobs2020Expanding).

In healthy human cells, CAMTA1 is highly expressed in the brain, particularly in regions associated with memory, such as the temporal and entorhinal cortex, and is involved in long-term memory formation. It also plays a significant role in the cerebellum, where it is involved in the control of Purkinje cell function and survival (Jacobs2020Expanding). CAMTA1's role in neuronal survival may be regulated by the MEF2/HDAC5/CaMKII pathway, and its absence can lead to severe ataxia and neuronal atrophy, as observed in CAMTA1 knockout mice (Long2014Ataxia).

CAMTA1 is also implicated in cardiac differentiation, where it activates a cardiac gene program in stem cells, highlighting its importance in stem cell differentiation towards a cardiac lineage (MullerBorer2012Calcium).

## Clinical Significance
Mutations and alterations in the CAMTA1 gene are associated with several neurological disorders and cancers. In humans, heterozygous chromosomal rearrangements in the CAMTA1 locus can lead to congenital cerebellar ataxia, a condition characterized by impaired motor coordination and cerebellar degeneration (Long2014Ataxia). De novo variants in CAMTA1, including nonsense, frameshift, and missense mutations, have been linked to a syndrome featuring spasticity, ataxia, and intellectual disability, with variable expression among patients (Wijnen2020De). 

CAMTA1 also functions as a tumor suppressor in various cancers. Its expression is downregulated in gliomas, including glioblastoma, where it inhibits cell proliferation and migration by regulating pathways such as AKT phosphorylation (He2021CAMTA1). In neuroblastoma, low CAMTA1 expression is an independent predictor of poor outcomes, and its ectopic expression can slow tumor growth and induce neuronal differentiation (Henrich2011CAMTA1). CAMTA1 is also implicated in ischemic stroke, where hypermethylation of its promoter may contribute to disease pathology by affecting cell cycle regulation (Liu2022CAMTA1). These findings highlight CAMTA1's significant role in both neurological and oncological conditions.

## Interactions
CAMTA1, a calmodulin-binding transcription activator, participates in various protein interactions that influence its function in cellular processes. In the context of epithelioid hemangioendothelioma (EHE), CAMTA1 is involved in the WWTR1-CAMTA1 gene fusion, resulting in the TAZ-CAMTA1 fusion protein. This fusion protein interacts with TEAD transcription factors, which are crucial for its tumorigenic activity. The interaction with TEAD is facilitated by a TEAD-interacting motif in the N-terminus of the fusion protein, essential for inducing cell transformation (Seavey2022Unraveling).

CAMTA1 also interacts with chromatin-remodeling complexes, including the SWI/SNF, NUA4/TIP60, COMPASS-like complexes, and the Ada-Two-A-containing complex (ATAC). These interactions are significant for the tumorigenic potential of the TAZ-CAMTA1 fusion protein, as they influence transcriptional activity and tumorigenesis (Seavey2022Unraveling).

In colorectal cancer, CAMTA1 forms a multi-protein complex with NFATc4 and PPP3CA, impacting chemoresistance to oxaliplatin. CAMTA1 negatively regulates NFATc4 expression, and its interaction with PPP3CA influences NFATc4 phosphorylation, affecting cancer cell behavior and drug resistance (Pan2022CAMTA1–PPP3CA–NFATc4). These interactions highlight CAMTA1's role in modulating transcriptional activity and cellular responses.


## References


[1. (He2021CAMTA1) Zongze He, Chen Yang, Yunsen He, Bo Gong, Cheng Yin, Jie Feng, Longyi Chen, Jian Tang, and Yong Chen. Camta1, a novel antitumor gene, regulates proliferation and the cell cycle in glioma by inhibiting akt phosphorylation. Cellular Signalling, 79:109882, March 2021. URL: http://dx.doi.org/10.1016/j.cellsig.2020.109882, doi:10.1016/j.cellsig.2020.109882. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2020.109882)

[2. (Wijnen2020De) Iris G. M. Wijnen, Hermine E. Veenstra-Knol, Fleur Vansenne, Erica H. Gerkes, Tom de Koning, Yvonne J. Vos, Marina A. J. Tijssen, Deborah Sival, Niklas Darin, Els K. Vanhoutte, Mayke Oosterloo, Maartje Pennings, Bart P. van de Warrenburg, and Erik-Jan Kamsteeg. De novo variants in camta1 cause a syndrome variably associated with spasticity, ataxia, and intellectual disability. European Journal of Human Genetics, 28(6):763–769, March 2020. URL: http://dx.doi.org/10.1038/s41431-020-0600-5, doi:10.1038/s41431-020-0600-5. This article has 6 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41431-020-0600-5)

[3. (Seavey2022Unraveling) Caleb Seavey, Ajaybabu Pobbati, and Brian Rubin. Unraveling the biology of epithelioid hemangioendothelioma, a taz–camta1 fusion driven sarcoma. Cancers, 14(12):2980, June 2022. URL: http://dx.doi.org/10.3390/cancers14122980, doi:10.3390/cancers14122980. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers14122980)

[4. (Jacobs2020Expanding) Eva Z. Jacobs, Kathleen Brown, Melissa C. Byler, Erika D’haenens, Annelies Dheedene, Lindsay B. Henderson, Jennifer B. Humberson, Richard H. van Jaarsveld, Farah Kanani, Robert Roger Lebel, Francisca Millan, Renske Oegema, Ann Oostra, Michael J. Parker, Lindsay Rhodes, Margarita Saenz, Laurie H. Seaver, Yue Si, Arnaud Vanlander, Sarah Vergult, and Bert Callewaert. Expanding the molecular spectrum and the neurological phenotype related to <scp>camta1</scp> variants. Clinical Genetics, 99(2):259–268, November 2020. URL: http://dx.doi.org/10.1111/cge.13874, doi:10.1111/cge.13874. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/cge.13874)

[5. (Liu2022CAMTA1) Yang Liu, Guohui Shang, Xuran Zhang, Fuyong Liu, Chi Zhang, Zhihao Li, Jing Jia, Yan Xu, Zhaojing Zhang, Shangdong Yang, Baixue Zhou, Yingying Luan, Yanyang Huang, Yue Peng, Tianyi Han, Ying He, and Hong Zheng. Camta1 gene affects the ischemia-reperfusion injury by regulating ccnd1. Frontiers in Cellular Neuroscience, September 2022. URL: http://dx.doi.org/10.3389/fncel.2022.868291, doi:10.3389/fncel.2022.868291. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fncel.2022.868291)

[6. (Henrich2011CAMTA1) Kai-Oliver Henrich, Tobias Bauer, Johannes Schulte, Volker Ehemann, Hedwig Deubzer, Sina Gogolin, Daniel Muth, Matthias Fischer, Axel Benner, Rainer König, Manfred Schwab, and Frank Westermann. Camta1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells. Cancer Research, 71(8):3142–3151, April 2011. URL: http://dx.doi.org/10.1158/0008-5472.can-10-3014, doi:10.1158/0008-5472.can-10-3014. This article has 77 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-10-3014)

[7. (Pan2022CAMTA1–PPP3CA–NFATc4) Ruijun Pan, Zhou Zhang, Hongtao Jia, Junjun Ma, Chao Wu, Pei Xue, Wei Cai, Xiaoping Zhang, and Jing Sun. Camta1–ppp3ca–nfatc4 multi-protein complex mediates the resistance of colorectal cancer to oxaliplatin. Cell Death Discovery, March 2022. URL: http://dx.doi.org/10.1038/s41420-022-00912-x, doi:10.1038/s41420-022-00912-x. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41420-022-00912-x)

[8. (Long2014Ataxia) Chengzu Long, Chad E. Grueter, Kunhua Song, Song Qin, Xiaoxia Qi, Y. Megan Kong, John M. Shelton, James A. Richardson, Chun-Li Zhang, Rhonda Bassel-Duby, and Eric N. Olson. Ataxia and purkinje cell degeneration in mice lacking the camta1 transcription factor. Proceedings of the National Academy of Sciences, 111(31):11521–11526, July 2014. URL: http://dx.doi.org/10.1073/pnas.1411251111, doi:10.1073/pnas.1411251111. This article has 35 citations.](https://doi.org/10.1073/pnas.1411251111)

[9. (MullerBorer2012Calcium) Barbara Muller-Borer, Gwyn Esch, Rob Aldina, Woohyun Woon, Raymond Fox, Nenad Bursac, Sylvia Hiller, Nobuyuo Maeda, Neal Shepherd, Jian Ping Jin, Mary Hutson, Page Anderson, Margaret L. Kirby, and Nadia N. Malouf. Calcium dependent camta1 in adult stem cell commitment to a myocardial lineage. PLoS ONE, 7(6):e38454, June 2012. URL: http://dx.doi.org/10.1371/journal.pone.0038454, doi:10.1371/journal.pone.0038454. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0038454)